Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomic study in newly diagnosed older multiple myeloma patients treated with melphalan + prednisone + thalidomide or lenalidomide + dexamethasone
2008-003486-58Phase 3Completed
- Sponsor
- Inter-Groupe Francophone du Myélome
- Start
- Nov 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple myeloma (MM) comparing Melphalan + prednisone + thalidomide with Lenalidomide + dexamethasone (2 arms). Primary endpoints: Prediction of survival, Prediction of best response and 1 more. Started Nov 2008; status: completed.
02
Drugs
melphalanprednisonethalidomidelenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2008-003486-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003486-58.